A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)

A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive Compulsive Disorder

This multicenter, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of bitopertin in combination with SSRI in participants with obsessive-compulsive disorder. Participants will be randomized to receive either bitopertin 30 milligrams (mg) or bitopertin 10 mg or placebo orally daily in addition to their background therapy with an SSRI. Participants will be allocated to one of two strata. Participants in Stratum 1 will start study drug on Day 1. Participants in Stratum 2 will receive placebo from Day 1 (placebo lead-in) and will then start study drug at the Week 2 visit. Participants in both strata will receive the study drug in addition to their background therapy with an SSRI until Week 16.

Study Overview

• Status: Completed
• Conditions: Obsessive-Compulsive Disorder
• Intervention / Treatment: Drug: Bitopertin; Drug: Placebo; Drug: SSRI

• Study Type: Interventional
• Enrollment (Actual): 99
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Alberta
    • Edmonton, Alberta, Canada, T6L 6W6
      • Chokka Center for Integrative Health
  • British Columbia
    • Kelowna, British Columbia, Canada, V1Y 2H4
      • Okanagan Clinical Trials
  • Nova Scotia
    • Halifax, Nova Scotia, Canada, B3S 1M7
      • True North Clinical Research-Halifax
    • Kentville, Nova Scotia, Canada, B4N 4K9
      • True North Clinical Research Kentville
  • Ontario
    • Hamilton, Ontario, Canada, L8S 1B7
      • McMaster University - MacAnxiety Research Centre
    • Mississauga, Ontario, Canada, L5M 4N4
      • Sunny Johnson Medical Research Associates Inc.; Medical Research Associates
    • Toronto, Ontario, Canada, M4W 2N4
      • START Clinic for Mood & Anxiety Disorders
• United States
  • California
    • Oceanside, California, United States, 92056
      • Excell Research
    • Stanford, California, United States, 94305
      • Stanford University School of Medicine
  • Connecticut
    • New Haven, Connecticut, United States, 06519
      • Yale University School of Medicine; Neuroscience Research Training Program
  • Florida
    • Leesburg, Florida, United States, 34748
      • Compass Research North, LLC
    • Orange City, Florida, United States, 3273
      • Medical Research Group of Central Florida
    • Saint Petersburg, Florida, United States, 33701
      • University of South Florida
    • Tampa, Florida, United States, 33613-4706
      • University of South Florida
  • Georgia
    • Decatur, Georgia, United States, 30030
      • iResearch Atlanta
    • Smyrna, Georgia, United States, 30080
      • Carman Research
  • Illinois
    • Chicago, Illinois, United States, 60637
      • Uni of Chicago; Centre For Advanced Medicine
  • Louisiana
    • New Orleans, Louisiana, United States, 70114
      • Louisiana Research Associates
  • Massachusetts
    • Boston, Massachusetts, United States, 02131
      • Boston Clinical Trials
    • Boston, Massachusetts, United States, 02114
      • Massachusetts General Hospital - East
  • Minnesota
    • Minneapolis, Minnesota, United States, 55454
      • Ambulatory Research Center (ARC), Department of Psychiatry
  • Mississippi
    • Flowood, Mississippi, United States, 39232
      • Precise Research Centers
  • Missouri
    • Saint Louis, Missouri, United States, 63141
      • St Louis Clinical Trials
  • New York
    • New York, New York, United States, 10029
      • Mount Sinai School of Medicine; Department of Psychiatry
    • New York, New York, United States, 10128
      • Medical Research Network - New York
    • Rochester, New York, United States, 14618
      • Finger Lakes Clinical Research
  • Ohio
    • Middleburg Heights, Ohio, United States, 44130
      • North Star Research
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73103
      • IPS Research Company
  • Pennsylvania
    • Norristown, Pennsylvania, United States, 19403
      • Keystone Clinical Studies, LLC
  • Rhode Island
    • Providence, Rhode Island, United States, 02906
      • Butler Hospital - Department of Psychiatry and Human Behavior
  • Tennessee
    • Memphis, Tennessee, United States, 38119
      • Clinical Neuroscience Solutions,Inc
  • Texas
    • Austin, Texas, United States, 78731
      • FutureSearch Trials, LP
  • Washington
    • Kirkland, Washington, United States, 98033
      • Eastside Therapeutic Resource
  • Wisconsin
    • Middleton, Wisconsin, United States, 53562
      • Dean Foundation

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Primary diagnosis of OCD as per Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
• On a stable dose of SSRI for at least 8 weeks prior to screening an between screening and Day 1
• An insufficient response to current treatment with an SSRI given at an adequate dose for at least 12 weeks prior to Day 1
• Females who are not postmenopausal or surgically sterile and who have (or may have) male sexual partners must agree to use two adequate methods of contraception as defined by protocol from the start of screening until 90 days after the last dose of study drug

Exclusion Criteria:

• Primary OCD symptom of hoarding
• More than two unsatisfactory trials within the last 2 years with different serotonin reuptake inhibitors (not including the current treatment with an SSRI) given in an adequate dose for at least 12 weeks
• Failure of more than three augmentation therapies within the last 2 years
• Undergoing acute behavioral therapy or having acute behavioral therapy that was completed less than 4 weeks prior to Day 1
• Any primary DSM-IV-TR Axis I disorder other than OCD
• Current or prior history of bipolar disorder, schizophrenia or other psychotic disorders, schizoaffective disorder, autism or autistic spectrum disorders, borderline personality disorder, or Gilles de la Tourette syndrome if symptoms have persisted into adulthood
• Any eating disorder within the last 6 months
• History of DSM-IV-TR-defined substance dependence and/or substance abuse in the last 6 months, with the exception of nicotine
• Previous treatment with bitopertin or another Glycine transporter 1 inhibitor
• Positive urine drug screening for cannabis, amphetamines (including 3,4-methylenedioxymethamphetamine [MDMA]/ecstasy), cocaine, barbiturate, and/or opiates
• Prior or current general medical condition that may impair cognition or other neuropsychiatric functioning
• Body mass index less than (<) 18.5 kilogram per square meter (kg/m^2) or greater than (>) 40 kg/m^2
• Pregnant or lactating women

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Bitopertin 30 mg; Participants in Stratum 1 will receive bitopertin 30 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI. Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 30 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI.	Drug: Bitopertin; Bitopertin once daily orally.; Other Names: RO4917838; Drug: Placebo; Placebo matched to bitopertin once daily orally.; Drug: SSRI; Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.
EXPERIMENTAL: Bitopertin 10 mg; Participants in Stratum 1 will receive bitopertin 10 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI. Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 10 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI.	Drug: Bitopertin; Bitopertin once daily orally.; Other Names: RO4917838; Drug: Placebo; Placebo matched to bitopertin once daily orally.; Drug: SSRI; Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.
PLACEBO_COMPARATOR: Placebo; Participants (both Stratum 1 and Stratum 2) will receive placebo from Day 1 to Week 16 in addition to their background therapy with an SSRI.	Drug: Placebo; Placebo matched to bitopertin once daily orally.; Drug: SSRI; Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change From Baseline in Total Score on Yale-Brown Obsessive Compulsive Scale (Y-BOCS) After 12 Weeks of Treatment	Stratum 1: Baseline (Day 1), Week 12; Stratum 2: Baseline (Week 2), Week 14

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score After 12 Weeks of Treatment		Stratum 1: Baseline (Day 1), Week 12; Stratum 2: Baseline (Week 2), Week 14
Percentage of Participants with Response as per Pre-defined Criteria Based on the Y-BOCS and CGI	Response will be defined as having: At least a 35 percent (%) reduction on the total Y-BOCS score from baseline. A much or very much improved on the Clinical Global Impression of Change (CGI-C) rating from baseline. A combination of at least 35% reduction on the total Y-BOCS score from baseline and much or very much improved on the CGI-C from baseline. Achieved remission, as shown by a total Y-BOCS score less than or equal to (≤)10.	Stratum 1: Baseline (Day 1) up to Week 12; Stratum 2: Baseline (Week 2) up to Week 14
Change From Baseline in Global Social Functioning Using Sheehan Disability Scale (SDS) Total Score After 12 Weeks of Treatment		Stratum 1: Baseline (Day 1), Week 12; Stratum 2: Baseline (Week 2), Week 14
Change From Baseline in Global Social Functioning Using SDS Domain Scores After 12 Weeks of Treatment		Stratum 1: Baseline (Day 1) up to Week 12; Stratum 2: Baseline (Week 2) up to Week 14
Change From Baseline in Obsessive Compulsive Inventory-Revised (OCI-R) Score After 12 Weeks of Treatment		Stratum 1: Baseline (Day 1) up to Week 12; Stratum 2: Baseline (Week 2) up to Week 14
Change From Baseline in Columbia Suicide Severity Rating Scale After 12 Weeks of Treatment		Stratum 1: Baseline (Day 1) up to Week 12; Stratum 2: Baseline (Week 2) up to Week 14
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) - Mental Component Summary After 12 Weeks of Treatment		Stratum 1: Baseline (Day 1) up to Week 12; Stratum 2: Baseline (Week 2) up to Week 14
Change From Baseline in SF-36 - Physical Component Summary After 12 Weeks of Treatment		Stratum 1: Baseline (Day 1) up to Week 12; Stratum 2: Baseline (Week 2) up to Week 14
Change From Baseline in SF-36 - Domain Scores After 12 Weeks of Treatment		Stratum 1: Baseline (Day 1) up to Week 12; Stratum 2: Baseline (Week 2) up to Week 14
Area Under The Concentration-Time Curve of Bitopertin		Pre-dose (0 hour) on Day 56 (Week 8), Day 84 (Week 12), Day 98 (Week 14), Day 112 (Week 16); 3 and 6 hours post-dose on Day 112 (Week 16)

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche

Publications and helpful links

General Publications

• Bandeira ID, Lins-Silva DH, Cavenaghi VB, Dorea-Bandeira I, Faria-Guimaraes D, Barouh JL, Jesus-Nunes AP, Beanes G, Souza LS, Leal GC, Sanacora G, Miguel EC, Sampaio AS, Quarantini LC. Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review. Harv Rev Psychiatry. 2022 Mar-Apr 01;30(2):135-145. doi: 10.1097/HRP.0000000000000330.

Study record dates

Study Major Dates

• Study Start (ACTUAL): December 31, 2012
• Primary Completion (ACTUAL): April 30, 2015
• Study Completion (ACTUAL): April 30, 2015

Study Registration Dates

• First Submitted: August 15, 2012
• First Submitted That Met QC Criteria: August 24, 2012
• First Posted (ESTIMATE): August 28, 2012

Study Record Updates

• Last Update Posted (ACTUAL): August 2, 2017
• Last Update Submitted That Met QC Criteria: July 31, 2017
• Last Verified: July 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Personality Disorders; Anxiety Disorders; Compulsive Personality Disorder; Obsessive-Compulsive Disorder
• Other Study ID Numbers: WN28137